This is the first publication to provide an in-depth description of the antitumor activity of sustained-release formulations of capsaicin. The research team was led by Associate Professor, Doctor of Biomedical Sciences Piyali Dasgupta, and Professor, Doctor of Biomedical Sciences, Monica Valentovic.
“This review is the first to provide a comprehensive overview of capsaicin formulations in human cancer.“Dasgupta, the respective author of the publication said.”Previous publications in the literature have only briefly addressed sustained-release formulations of capsaicin. “
The nutrient capsaicin exhibits potent growth inhibitory activity in a wide range of human cancers. However, the clinical applications of capsaicin as a possible antineoplastic agent have been hindered by three factors – poor solubility, low bioavailability, and pungent taste.
“Taking capsaicin by mouth is associated with undesirable side effects such as stomach cramps, nausea, a burning sensation in the intestines, and gastrointestinal irritation.“Valentovic, a senior author on the publication said.
“One strategy to overcome these disadvantages is to develop different delivery systems, such as encapsulating capsaicin in long-acting extended-release drug delivery systems that may allow capsaicin levels More consistent may be more effective as anticancer agents. “